Vis enkel innførsel

dc.contributor.authorBorssén, Magnus
dc.contributor.authorNordlund, Jessica
dc.contributor.authorHaider, Zahra
dc.contributor.authorLandfors, Mattias
dc.contributor.authorLarsson, Pär
dc.contributor.authorKanerva, Jukka
dc.contributor.authorSchmiegelow, Kjeld
dc.contributor.authorFlægstad, Trond
dc.contributor.authorJónsson, Ólafur Gísli
dc.contributor.authorFrost, Britt-Marie
dc.contributor.authorPalle, Josefine
dc.contributor.authorForestier, Erik
dc.contributor.authorHeyman, Mats
dc.contributor.authorHultdin, Magnus
dc.contributor.authorLönnerholm, Gudmar
dc.contributor.authorDegerman, Sofie
dc.date.accessioned2019-04-24T12:01:42Z
dc.date.available2019-04-24T12:01:42Z
dc.date.issued2018-03-05
dc.description.abstract<p><i>Background</i>: Few biological markers are associated with survival after relapse of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In pediatric T-cell ALL, we have identified promoter-associated methylation alterations that correlate with prognosis. Here, the prognostic relevance of CpG island methylation phenotype (CIMP) classification was investigated in pediatric BCP-ALL patients.<p> <p><i>Methods</i>: Six hundred and one BCP-ALL samples from Nordic pediatric patients (age 1–18) were CIMP classified at initial diagnosis and analyzed in relation to clinical data.<p> <p><i>Results</i>: Among the 137 patients that later relapsed, patients with a CIMP− profile (<i>n</i> = 42) at initial diagnosis had an inferior overall survival (pOS<sub>5years</sub> 33%) compared to CIMP+ patients (<i>n</i> = 95, pOS<sub>5years</sub> 65%) (<i>p</i> = 0.001), which remained significant in a Cox proportional hazards model including previously defined risk factors.<p> <p><i>Conclusion</i>: CIMP classification is a strong candidate for improved risk stratification of relapsed BCP-ALL.<p>en_US
dc.description.sponsorshipSwedish Cancer Society Swedish Childhood Cancer Foundation Medical Faculty of Umeå University Lion’s Cancer Research Foundation Umeå University Umeå Pediatric Clinic Research Foundation Kempe foundations Magnus Bergvalls Foundation Uppsala-Umeå Comprehensive Cancer Consortium Västerbotten County Council Swedish Research Council Knut and Alice Wallenberg Foundationen_US
dc.descriptionSource at <a href=https://doi.org/10.1186/s13148-018-0466-3>https://doi.org/10.1186/s13148-018-0466-3. </a> © The Author(s). 2018en_US
dc.identifier.citationBorssén, M., Nordlund, J., Haider, Z., Landfors, M., Larsson, P., Kanerva, J. ... Degerman, S. (2018). DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia. <i>Clinical Epigenetics</i>, 10:31. https://doi.org/10.1186/s13148-018-0466-3en_US
dc.identifier.cristinIDFRIDAID 1592163
dc.identifier.doi10.1186/s13148-018-0466-3
dc.identifier.issn1868-7075
dc.identifier.issn1868-7083
dc.identifier.urihttps://hdl.handle.net/10037/15224
dc.language.isoengen_US
dc.publisherBMCen_US
dc.relation.journalClinical Epigenetics
dc.rights.accessRightsopenAccessen_US
dc.subjectDNA methylationen_US
dc.subjectBCP-ALLen_US
dc.subjectPrognosisen_US
dc.subjectCIMPen_US
dc.subjectRelapseen_US
dc.subjectRisk stratificationen_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleDNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemiaen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel